Express Mail Label No.: EV074975407US

ate of Deposit: March 7, 2003

Attorney Docket No.: 23239-301A

(Formerly 23239-539)

HICOSHOCK PROPERTY STOCK

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Ellington, et al.

APPLICATION

09/661,658

Examiner:

Gibbs, Terra

NUMBER:

September 14, 2000 FILING DATE:

Art Unit:

1635

For:

ALLOSTERICALLY REGULATED RIBOZYMES

Box IDS

Commissioner for Patents Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references. Previous counsel cited thirty United States Patent Documents, four Foreign Patent Documents and three other pieces of journal art without labeling the art alpha-numerically. Present counsel takes the previous citations into account and presents this Supplemental Information Disclosure beginning with the thirty-first United States Patent Document, fifth Foreign Patent Document and the fourth piece of journal art labeled alpha-numerically.

Note that B7 and B10 are foreign language documents. English language abstracts have been provided for these references as documents B11 and B12.

This Supplemental Information Disclosure Statement is being filed within three months of the mailing date of the International Search Report for PCT/ US 01/19302 that corresponds to the above-identified application. Accordingly, no fee or certification is believed required.

A copy of each of the references is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that

Page 2 of 2

Applicants: Ellington, et al. U.S.S.N.: 09/661,658

the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 Reference No. 23239-301A.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Attorney for Applicants

c/o MINTZ, LEVIN, COHN, FERRIS GLOVSKY AND POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241


Dated: March 7, 2003

TRA 1771067v1

Express Mail Label No.: EV074975407US

Attorney Docket No.: 23239-301A TECH CENTER 1600/2900

(Formerly 23239-539)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Ellington, et al.

APPLICATION

09/661,658

Examiner:

Gibbs, Terra

NUMBER:

FILING DATE:

September 14, 2000

Art Unit:

1635

FOR:

ALLOSTERICALLY REGULATED RIBOZYMES

BOX IDS

Commissioner for Patents Washington, D.C. 20231

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
- 2. Modified Form 1449/PTO (1 page), in duplicate;
- 3. Copies of cited references A31, B5-B12, and C4-C10; and
- 4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 23239-301A. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

PATENT TRADEMARK OFFICE

Ivor R. Elrifi, Reg. No. 39,529

Attorney for Applicants

c/o MINTZ, LEVIN, COHN, FERRIS GLOVSKY AND POPEO, P.C.

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000 Fax: (617) 542-2241

Dated: March 7, 2003

TRA 1771092v1

Express Mail No.: EV074975407US

Date of Deposit: March 7, 2003

Please type a plus sign (+) in this box

+

09/661,658 **Application Number** odified Form 1449/PTO September 14, 2000 **Filing Date** Ellington First Named Inventor INFORMATION DISCLOSURE 1635 STATEMENT BY APPLICANT Group Art Unit Gibbs, Terra C **Examiner Name** 23239-301A (use as many sheets as necessary) Attorney Docket Number -(Formerly 23239-539)

				U.S. PATENT DOCUMENTS				
Exam	Cite	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate	
Initials			08/22/95	Cathcart, et al.			08/07/92	
	A31	5,443,791	08/22/93	Odinouri, or an		<u> </u>		

				FOREIGN PATENT DOCUMENTS			
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
		wo	96/06944	The General Hospital Corporation	03/07/96		
	B6	wo	98/27104	Yale University	06/25/98		
	B7	wo	99/16781	Roche Diagnostics GMBH	04/08/99		Х
	B8	wo	99/57561	Ammann, Kelly	11/11/99		
	B9	wo	00/43534	Somalogic, Inc.	07/27/00		
		FR	2 633 310	Institut Pasteur	12/29/89		Х
	B10 B11	FR	2 633 310	Institut Pasteur (English Language Abstract Only)	12/29/89		
	B12	wo	99/16781	Roche Diagnostics GMBH (English Language Abstract Only)	04/08/99		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS					
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.			
	C4	Cox, et al. (1998). Biotechnol Prog 14: 845-850.			
	C5	Ellington, Andrew (1994). Curr Biol 4(5): 427-429.			
	C6	International Search Report for PCT US 01/19302, mailed January 22, 2003.			
	C7	Koizumi, et al. (1999). Nat Struct Biol 6(11): 1062-1071.			
	C8	Marshall and Ellington (1999). Nat Struct Biol 6(11): 992-994.			
	C9	Robertson and Ellington (2000). Nucl Acid Res 28(8): 1751-1759.			
	C10	Xu, et al. (1996). Proc Natl Acad Sci USA 93(15): 7475-7480.			

Carial Na	s reference is not provided as it was previously cited by or su , filed, and relied up 20 (continuation, continuation-in-part, and divisional application	, and relied upon for an earner than 9			
Examiner Signature		Date Considered			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.